

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR THE UNITED STATES OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.



PRESS RELEASE

Stockholm 11 May 2011

Sobi publishes prospectus supplement regarding the rights issue

Swedish Orphan Biovitrum AB (publ) ("Sobi") today publishes a supplement to the prospectus made public on 5 May 2011 in respect of the invitation to subscribe for shares in Sobi. The prospectus supplement includes Sobi's and Biogen Idec's announcement dated 9 May 2011 that the European Medicines Agency (EMA) has adopted an opinion agreeing to the pediatric investigational plan for the companies' long-lasting, fully-recombinant Factor IX Fc fusion protein (rFIXFc).

The prospectus supplement has been approved by and registered at the Swedish Financial Supervisory Authority (the SFSA) and is available on the website of the SFSA www.fi.se, on Sobi's website www.sobi.com, on Carnegie's website www.carnegie.se and on Handelsbanken's website www.handelsbanken.se/investmentoffer.

Those investors who have applied for or in any other manner consented to the purchase or subscription of securities covered by the rights issue, before the publication of the prospectus supplement, are entitled to withdraw their application or consent up to and including 18 May 2011 (i.e. within five working days from the publication of the prospectus supplement). Such withdrawal must be submitted in writing to Carnegie Investment Bank AB, Transaction Support, SE-103 38 Stockholm, Sweden. If the subscription application was submitted through a trustee, the investor shall contact its trustee regarding any withdrawal. Subscriptions that are not withdrawn will remain binding and those subscribers who wish to remain as subscribers do not need to take any further action.

For additional information, please contact

Åsa Stenqvist, VP Communications and Investor Relations

Telephone: +46 8-697 20 00

About Swedish Orphan Biovitrum (Sobi)

Sobi is a leading European specialty pharmaceutical company. The company is focused on providing and developing specialty pharmaceuticals for patients with rare diseases and significant medical needs. The portfolio comprises about 60 marketed products, as well as projects in late clinical phase. Key therapeutic areas are hematological diseases, autoimmune diseases, hereditary metabolic disorders and therapeutic oncology. In 2010 Sobi had revenues of SEK 1.9 B and approximately 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com.

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR THE UNITED STATES OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 11 May 2011 at 12.15 p.m. CET.

IMPORTANT INFORMATION

The information in this press release is not intended for distribution, publication or public release, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, Singapore, South Africa, Switzerland, the United States or any other jurisdiction where the distribution of this press release may be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction.

The information in this press release is not an offer to sell or a solicitation to buy shares. This press release is not a prospectus under the Prospectus Directive 2003/71/EC. A prospectus will be prepared and published in accordance with the Prospectus Directive and will thereafter be made available by the Company. Investors shall not subscribe for securities referred to in this press release other than on the basis of the information which will be included in such prospectus.

The information in this press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the "Securities Act") or under the securities laws of any state or other jurisdiction in the United States, and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offer of securities in the United States.

The information in this press release may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part may be prohibited. Failure to comply with these instructions may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

This press release may contain forward-looking statements. Words such as "expect", "believe", "estimate", "plan" and "forecast" in this press release are intended to indicate forward-looking statements. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to risks and uncertainties. All these forward-looking statements are based on the expectations and assumptions of the management and are deemed reasonable but uncertain and difficult to predict. Actual outcomes and results may differ significantly from the forward looking statements. The Company does not intend, nor undertakes, to update any such forward looking statements.